Listen to today’s podcast here!
Researchers recently found that there is no connection between heart failure hospitalizations and DPP-IV inhibitor treatment in patients with type 2 diabetes. This finding came from a study completed at Truven Health Analytics out of Bethesda, Maryland. Researchers evaluated data from insurance claims for patients who initiated treatment on DPP-IV inhibitors between August 2010 and August 2013.
The results found that there is no real difference in the change for heart failure hospitalization among patients regardless of whether they were treated with DPP-IV inhibitors or sulfonylureas. Researchers concluded the study by reiterating that it is an important part of medical practice to continue monitoring patients with type 2 diabetes for the symptoms of heart failure, including edema and shortness of breath.
These findings were published in Diabetes Care on January 6, 2016.